In the 100 years since TURP was invented, surgical retreatment has meant one thing: a BPH treatment performed a second time. In many of today’s clinical studies for BPH, surgical retreatment rate points to study subjects who undergo repeat surgical treatment during the duration of a clinical study.
Simple enough. So why has there been renewed discussion on this topic?
It was proposed during the virtual 2020 AUA annual meeting that perhaps the term “retreatment” has been reported differently and to different levels of detail in BPH clinical trials, which led to a call for consensus in definitions.1 This lack of consistency may potentially lead to misinterpretation of data, or bias, in assessing retreatment outcomes. Clarity and consistency is key in discussing such critical factors. Find more HERE in the Urology Times article, Making Sense of the Reintervention Rate for BPH.
The UroLift® System is the number one minimally invasive BPH treatment chosen by urologists and their patients in the U.S.2 There are good reasons for that, including its reliable durability!3
In the L.I.F.T. study, the surgical retreatment rate for the UroLift® System is reported as 13.6% at five years.3 That’s 2-3% per year, which compares favorably with the retreatment rate of TURP.1
Let’s get real: there is no need to obscure the simple definition of surgical retreatment.
You can change your appropriate BPH patients’ journeys for the better, with confidence, by offering them the UroLift® System.
References
1. Eure, Making Sense of the Reintervention Rate for BPH, Urology Times March 2021
2. U.S. 2022 estimates based on US Market Model 2022-24 (5-17-22 FINAL), which is in part based on Symphony Health PatientSource® 2018-21, as is and with no representations/warranties, including accuracy or completeness.
3. Roehrborn, Can J Urol 2017
MAC02615-01 Rev A